Get started
NOVAVAX INCNOVAVAX INCNOVAVAX INC

NOVAVAX INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

NVV1 trade ideas

NVAX | Lets Get It | OversoldNovavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NASDAQ:NVAXLong
by DivergenceSeeker
1
Looking for a reversal in fortune for NOVAVAX Short Term We look to Buy at 30.75 (stop at 26.75) Bullish Outside Day posted, a pattern that often indicates the end of a bearish run and the start of a new upward bias. Prices have continued the bullish move higher and resulted in 3 consecutive positive days. Although the bears are in control, the stalling negative momentum indicates a turnaround is possible. In line with the possible early stages of a reverse head & shoulders pattern and the strong rejection of dips, we look to set longs in anticipation of a swing higher. Our profit targets will be 42.75 and 47.70 Resistance: 37.92 / 44.52 / 47.70 Support: 28.30 / 24.00 / 20.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:NVAXLong
by Saxo
Bullish hammer on Novavax?Novavax Short Term We look to Buy at 35.94 (stop at 32.00) Posted a Bullish Hammer Bottom on the Daily chart. Although the anticipated move higher is corrective, it does offer ample risk/reward today. We therefore, prefer to fade into the dip with a tight stop in anticipation of a move back higher. Expect trading to remain mixed and volatile. Our profit targets will be 49.43 and 60.00 Resistance: 45.00 / 63.00 / 76.00 Support: 35.00 / 23.12 / 15.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:NVAXLong
by Saxo
6
Is NVAX oversold following its earnings miss?A few days ago, NVAX gapped down 30 percent on a large earnings miss. This means that now NVAX is down over 87% from its ATH. Why I think NVAX is a buy right now The stock had a minor rally off a long term support level extending to 2020, and has higher lows than during the previous rally off this support level. It is trading at a heavily discounted price/sales of 2.55, far below its peak p/s at 249.16. There is a large upside, with the nearest strong resistance level roughly 50% above the current price. I'm buying in at around 42.2 with a high risk reward ratio. I'll be targeting a roughly 20% return with a 5% stop.
NASDAQ:NVAXLong
by spiritualhealer117
this vaccine trade popped in february 2021, can it recover some?all gas no breaks with a full tank and a full trunk. this covid vaccine stock enjoyed a huge runup to the release of the vaccine, but since has languished on the monthly as it lost over 90% of the price high. im not looking towards this as a long term investment, but im buying the rumor that nvax is announcing new trials or a variant innoculation or at least some catalyst and selling the news of that catalyst as well as the release of the vaccine/start of trial. if we stay above pivot, im aiming for upper horizontals and if we fall beneath it im looking for the lower horizontals. im not looking for a huge long on this thing, just maybe some monthly snap back and a move to close gap.
NASDAQ:NVAX
by cerealpatterns
No Brainer Mid-Long TermEmphasizing the mid-long term reward outweighs the near-term risk here using statistics in confluence with wyckoff and corrective structure: Here is what I see, accumulation began early 2022 and attempted a spring in April, but NVAX just didn't have the near-term catalysts it needed to follow through with a sign of strength (especially in the general corrective market environment of 2022).. so it began a new accumulation phase at lower levels. : - I use control charts that I designed in R, which help me gauge the stability of the current price levels w.r.t. moving averages over near- to mid-term periods (long term NVAX is cyclical and that is a whole different monster, requires more sophisticated time series and beyond the scope of this post). The 4 different CCs in the pasted image in this chart are 4 different relationships that have provided me, in general, with good results when all 4 are consistent in their interpretation. What is important here is that for NVAX to continue trading at current levels would be an anomaly, statistically.. however, if it maintains these levels for extended periods then they would become the new norm (the latter is least probable here) - downside risk near-term before NVAX become an extreme anomaly (which has 98% bounce rate, current level around 86%-93% bounce rate) is the 20-26 range - near term tendency of price is to bounce to 52-63 - generally there is an equal and opposite reaction when a name gets this unstable down it will over compensate on the move up. Overcompensation range that I am actually expecting (catalyst will be approval, or whatever they conjur up to pump it, idc): 67-73 ** Using confluence with ARIMA time series, wyckoff expectation of seeing an SoS here off this new spring that is forming, and dynamics of control charts (I use these to confirm accumulation or distribution as well), it would make most sense to see an over-reaction bounce soon centered around some hyped news to around 67-73, followed by a pullback into the stable range around 52, and then continuation from there. The yellow paths are just illustrative, solid line near term trajectory, dashed line the general mid-term expectation for price action.. again, illustrative for now.
NASDAQ:NVAXLong
by JerryManders
9
NOVAVAX Long term countWeekly update with my long-term scenario... It looks short-term bearish, but it is the best scenario for long-term bulls according to Elliott waves! It has a gap fill in the low 20s, and then a wave (c) super cycle will start. As you see on the side there is a gap of volume below 35 and then a huge amount of volume from 10s-20s, I am not saying we will go there, but needs to be served somehow, maybe 20-25... The catalyst from the revisit of the lows maybe will be a market crash or lower covid cases and no new orders, maybe a new pill, I don't know... But I think we are not out of the woods just yet, not so easy!
NASDAQ:NVAX
by FiboSnail
Novavax - Wassup?Novavax NVAX is actually lining up pretty well... from about 240, it tanked to 40, and on Friday, it gained 11% to close the week at 57.15. This caught my attention as it cleanly broke out of trendlines, breaking out also from a bearish divergence, on BOTH the weekly and daily chart. IMHO, it appears to be in technical and fractal alignment. Weekly chart bounced off a major support two weeks ago, and the last week continued the previous week's bullish end. On the daily chart, Friday's close was the highest daily close in about 5 weeks. with a strong candle closing draws obvious bullish attention. Target 80, then 125. Support at 53 and 50.
NASDAQ:NVAXLong
by Auguraltrader
3
Don't sleep on NVAXWhat I am seeing here is the most sophisticated accumulation setup I have come across in the market - and CO has been doing this for NVAX cyclically every pandemic in the past. The company focuses on stopping the propagation of viruses, however, CO spins it by propagating demand (like a virus) and absorbing supply which they injected intentionally at strategic stages downstream! This is nice, nested markup activation. Sorry if its difficult to see clearly, that is for me. I will post a followup idea where I zoom in and discuss the projected most likely scenarios. But here is the bigger picture that I wanted to present as surprisingly high probability targets/critical levels to watch in the coming weeks. I used MRNA epic run in summer 2021as a proxy, as well as a general method that I developed to make such predictions on Markup phases. - Minimum Target by August is 119 (given that 79 can be breached in time - will discuss the time component in followup post). - Sweet spot/target spot I'm expecting by mid September is 217-229 - If they invoke chaos w.r.t. demand and break above 171 by Jul 25th, then max target by mid-Septemer is ~350 (when such a squeeze occurs as it did last Jan, and it is highly likely is what we are about to see, establishing a point target is nearly impossible so the max target range 300-400). *** NVAX activated markup on Friday July 1st. There is a nested activation that will trigger if it gets above 63-65 by July 11th-18th, and there is an carryover activation level at 171 which regained the capacity for activation on 3/21/2022 - for it to be reactivated, the price must break above it by 7/25/2022. Smuggled between these activation levels, there are price (%) doubling and period halving bifurcation levels where the price will gap if hit. These require a massive squeeze, which NVAX is more than capable of currently - these levels are at 65, 83, and 217. The next supply/demand equilibrium point is July 5th, so good chance they will announce approval before the bell tomorrow. Once time crosses the equilibrium point there are windows where the activation and bifurcation levels remain in effect. So if price keeps up with time or exceeds it, here is what I expect: - Gap up Tuesday to trigger 63-65 and then continue to resistance at 79 by July 7th-8th - After rejection from 79, it will pullback and test 65 for support, if that holds and it bounces I'd expect the 2nd wave of the squeeze to kick in and drive it above 79. They have the bifurcation set in place at 83 to gap it toward 100 once it hits 83. - From there it gets tricky, because there is another nested markup activator that I haven't even discussed because its beyond the scope of this post, it was a distribution phase beginning in Jan 2022.. my theory is that it serves the purpose of kicking in the 3rd and final phase of the squeeze once 83 is breached. It is the only way I see this getting over 119. There is an attractor at 106 that could allow them to re-accumulate there in order to breach 119. If they make it to 131 it will begin a rally similar to what MRNA saw in 2021. For NVAX, it looks like above 131 will open the door for 171, then gap to 217-229, and finally run to 300-400 where they will begin the final distribution pertaining to Covid-19. When its all said and done this will make its way back down to ~20 in 2023, likely even lower by 2024.
NASDAQ:NVAXLong
by JerryManders
9